IPP Bureau
Max Healthcare CMD Abhay Soi recognised as one of the highest individual tax payers in India
By IPP Bureau - July 27, 2024
Abhay Soi, who had paid an income tax of approximately Rs 400 crore in the assessment year 2023-24 has been recognised as the “Top Individual tax payers having gross tax payable > Rs 10 Lakhs"
USAID and Takeda launch dengue prevention campaign
By IPP Bureau - July 27, 2024
Campaign launched to spread awareness regarding dengue prevention and control
Mankind Pharma to acquire 100% stake in Bharat Serums from Advent for Rs. 13,630 Cr
By IPP Bureau - July 26, 2024
Acquisition in line with Mankind’s stated objective to expand its presence in high entry barrier complex portfolios and high potential OTX brands
Emcure Pharmaceuticals signs PPA with Sunsure Energy for solar power
By IPP Bureau - July 26, 2024
The partnership will significantly advance their sustainability initiatives by meeting around 67% of their power requirements for these plants
Pfizer announces positive topline results from Phase 3 study of hemophilia A gene therapy candidate
By IPP Bureau - July 26, 2024
Giroctocogene fitelparvovec study meets primary and key secondary objectives of superiority compared to prophylaxis
Glenmark Life Sciences posts Q1 FY25 PAT at Rs. 111.48 Cr
By IPP Bureau - July 26, 2024
Glenmark Life Sciences has reported total income of Rs. 594.109 crores during the period ended June 30, 2024
USFDA inspects Gland Pharma’s Dundigal facility
By IPP Bureau - July 26, 2024
The inspection was concluded with two 483 observations
European Commission approves Pfizer’s Durveqtix gene therapy for adults with hemophilia B
By IPP Bureau - July 26, 2024
A one-time dose of DURVEQTIX has reduced bleeds post-treatment compared to standard of care with a median annualized bleed rate (ABR) of zero bleeds (range 0 to 9.9)
Cupid widens e-Commerce presence on leading Indian platforms
By IPP Bureau - July 26, 2024
This strategic move aims to make Cupid's high-quality products more accessible to consumers nationwide
Sun Pharmaceutical receives USFDA approval for oral JAK inhibitor ‘Leqselvi’
By IPP Bureau - July 26, 2024
Leqselvi delivered statistically significant efficacy across two Phase 3 clinical trials
Piramal Pharma Q1 FY25 net loss narrows
By IPP Bureau - July 26, 2024
EBITDA grew by 31% YoY with EBITDA margin of 11%, a YoY improvement of over 170bps vs. Q1FY24
Laurus Labs posts Q1 FY25 consolidated PAT at Rs. 12.51 Cr
By IPP Bureau - July 26, 2024
Laurus Labs has reported total income of Rs. 1,197.42 crores during the period ended June 30, 2024
Emmes partners with Miimansa AI to accelerate adoption of Generative AI in clinical research
By IPP Bureau - July 25, 2024
The partnership will focus on creating capabilities for quickly and accurately processing vast amounts of clinical data
Gland Pharma receives USFDA’s tentative approval for Latanoprostene Bunod Ophthalmic Solution
By IPP Bureau - July 24, 2024
The product is bioequivalent and therapeutically equivalent to the reference listed drug
Shilpa Biologicals receives registration approval for Adalimumab from Morocco, MoH
By IPP Bureau - July 24, 2024
Shilpa Biologicals has developed high concentration adalimumab (100 mg/mL)
